Lupin gains on launching Darunavir Tablets
Lupin is currently trading at Rs. 822.10, up by 4.95 points or 0.61% from its previous closing of Rs. 817.15 on the BSE.
The scrip opened at Rs. 823.15 and has touched a high and low of Rs. 830.30 and Rs. 818.35 respectively. So far 22411 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 830.30 on 05-Jun-2023 and a 52 week low of Rs. 592.55 on 17-Jun-2022.
Last one week high and low of the scrip stood at Rs. 830.30 and Rs. 780.00 respectively. The current market cap of the company is Rs. 37185.44 crore.
The promoters holding in the company stood at 47.08%, while Institutions and Non-Institutions held 42.52% and 10.40% respectively.
Lupin has launched Darunavir Tablets, 600 mg and 800 mg, to market a generic equivalent of Prezista Tablets of Janssen Products, LP. Darunavir Tablets, 600 mg and 800 mg (RLD Prezista) had estimated annual sales of $308 million in the U.S. (IQVIA MAT March 2023).
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
